Encouraging Avastin results in glioblastoma multiforme

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

Encouraging Avastin results in glioblastoma multiforme

DALLAS—Phase II data showed 6-month progression-free survival in 36% of relapsed glioblastoma patients given Avastin (bevacizumab) alone and 51% given Avastin plus irinotecan (Camptosar), compared with historical estimates of 15%. UCLA's Timothy Cloughesy, MD, reported the findings at the Society for Neuro-Oncology annual meeting.

Articles in this issue
Third-line single-agent cetuximab ups overall survival
Modern multislice CT propels pancreas imaging forward
Sorafenib gets ok for liver cancer
Celgene to acquire Pharmion
Novacea halts ASCENT-2 trial
RT/temozolomide raises possibility of cure in glioblastoma
Brachytherapy as effective in younger as in older men
MMA not harming patients
Kinase inhibitor may prevent RT-induced lung injury
FDA approves lower starting dose for dasatinib for CML
Encouraging Avastin results in glioblastoma multiforme
Sunitinib is cost-effective in metastatic renal ca patients
The role of imaging in microsphere therapy of liver mets
Free website offers chemo order forms
MR tops x-ray and scintigraphy for detecting bone mets
Related Videos
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Related Content
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma

April 23rd 2024
Article

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Oncology-On-The-Go Podcast: Signaling Pathways in Glioblastoma Relapse

May 1st 2023
Podcast

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Promising Glioma Therapy Options

Promising Glioma Therapy Options

December 21st 2018
Podcast

Dr. James Perry speaks with Cancer Network about glioma therapy options and the future of brain cancer treatment.

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

CAN-3110 Earns FDA Fast Track Designation in Recurrent High-Grade Glioma

February 13th 2024
Article

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results in both Study 3b and Study ANBL0032.

Eflornithine Is Approved by the FDA for High-Risk Neuroblastoma

December 13th 2023
Article

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results from Study 3b and Study ANBL0032.